Immunohistochemical examination of tumor cells showed CD3 was positive in 98% (86/88) of patients, CD4 was positive in 92% (81/88), CD10 in 57% (50/88), CD30 in 80% (70/88), BCL-6 in 56% (49/88), and CXCL13 in 88% (77/88) in patients with AITL, and the high expression rates of Ki67 (≥ 45%) were 59% (52/88) (Table 2 ). The gene discussed is CD4; the disease is angioimmunoblastic T-cell lymphoma.